The DOI matches its Crossref record; 160 of the 163 references it cites were found in a registry or an index.
Current challenges in biotherapeutic particles manufacturing
Open accessAbstract
Introduction: The development of novel complex biotherapeutics led to new challenges in biopharmaceutical industry. The potential of these particles has been demonstrated by the approval of several products, in the different fields of gene therapy, oncolytic therapy, and tumor vaccines. However, their manufacturing still presents challenges related to the high dosages and purity required.Areas covered: The main challenges that biopharmaceutical industry faces today and the most recent developments in the manufacturing of different biotherapeutic particles are reported here. Several unit operations and downstream trains to purify virus, virus-like particles and extracellular vesicles are described. Innovations on the different purification steps are also highlighted with an eye on the implementation of continuous and integrated processes.Expert opinion: Manufacturing platforms that consist of a low number of unit operations, with higher-yielding processes and reduced costs will be highly appreciated by the industry. The pipeline of complex therapeutic particles is expanding and there is a clear need for advanced tools and manufacturing capacity. The use of single-use technologies, as well as continuous integrated operations, are gaining ground in the biopharmaceutical industry and should be supported by more accurate and faster analytical methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although AAVs are most widely used vectors in retinal gene therapy, they remain difficult and costly to produce.16–18”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Production methods are difficult to scale from the bench to a commercial size, often with lower yields and efficiency.17”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Optimized exosome isolation protocol for cell culture supernatant and human plasma
Lobb, R. J., Becker, M., Wen Wen, S., Wong, C. S. F., Wiegmans, A. P., Leimgruber, A., & Möller, A. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27031 · Cited by 1,705 · cited 2×
“yields for viral particles and extracellular vesicles [78,85,86].”
BackgroundMethodAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“actively investigated for gene therapy purposes [94].”
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312 · cited 1×
“AAVs [39,40], influenza [41], lentivirus [42] and other viral vaccines [43,44].”
BackgroundProduction and purification of lentiviral vectors
Tiscornia, G., Singer, O., & Verma, I. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.37 · Cited by 996 · cited 1×
“AAVs [39,40], influenza [41], lentivirus [42] and other viral vaccines [43,44].”
BackgroundSokolova, V., Ludwig, A.-K., Hornung, S., Rotan, O., Horn, P. A., Epple, M., & Giebel, B. (2011) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.05.013 · Cited by 851
Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking
Murphy, D. E., de Jong, O. G., Brouwer, M., Wood, M. J., Lavieu, G., Schiffelers, R. M., & Vader, P. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0223-5 · Cited by 705
Nordin, J. Z., Lee, Y., Vader, P., Mäger, I., Johansson, H. J., Heusermann, W., Wiklander, O. P. B., Hällbrink, M., Seow, Y., Bultema, J. J., et al. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.003 · Cited by 678 · cited 1×
“Regarding extracellular vesicles, PES or RC membrane devices with 100 kDa have been used, but their behavior in the purification of these particle has not been fully explored yet [76,84,86].”
MethodExtracellular vesicles and viruses: Are they close relatives?
Nolte-‘t Hoen, E., Cremer, T., Gallo, R. C., & Margolis, L. B. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605146113 · Cited by 494
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
Research works printed but not linked: 18
- Reiter M, 2005, Method for large scale production of virus antigen
- Kamilla S, Virgínia PC. Recombinant Glycoprotein Production: Methods and Protocols. New York: Springer; 2018.
- Reimer CB, 1966, Am Assoc Adv Sci, 152, 1379
- Morita M, 2011, Hitachi Rev, 60, 257
- Xenopoulos A, 2015, EMD Millipore Webinar Ser
- Iammarino M, 2007, Bioprocess Int, 38
- Gousseinov E, 2014, Bioprocess Int, 12, 59
- Oxford Biomedica plc. SecNunc™ for AAVs, lentiviral vectors and adenovirus (Application Note), 2019, p. 1–2.
- Healthcare GE, 2014, Concentration and diafiltration of cell-derived, live influenza virus using 750 C hollow fiber filter cartridge (Application note 29-0928-26 AA)
- Mietzsch M, 2015, Human., 12
- Hansen SP, 2015, Purification of vaccinia viruses using hydrophobic interaction chromatography
- Gagnon P, 2009, Encycl Ind Biotechnol
- Gagnon P, 2008, BioProcess Int
- Lima TM, 2019, Vaccine., 1
- Shin H, 2018, PLoS One, 13, 1
- Jagschies G, 2018, Biopharmaceutical processing - development, design, and implementation of manufacturing processes
- Yang L, 2016, Front Microbiol, 7
- Kingstad-Bakke BA, 2018, Zika virus vaccines using virus-like particles
Cited by
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 327
Tariq, H., Batool, S., Asif, S., Ali, M., & Abbasi, B. H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.790121 · Cited by 248
“…viral nucleocapsid proteins is primarily responsible for the formation of these VLPs. Non-enveloped VLPs are still being investigated as preferable candidates for developing subunit vaccines against several pathogenic diseases as they are easier to produce and purify (Naskalska and Pyrć, 2015).”
BackgroundTechnological advances towards extracellular vesicles mass production
Grangier, A., Branchu, J., Volatron, J., Piffoux, M., Gazeau, F., Wilhelm, C., & Silva, A. K. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113843 · Cited by 174
“Finally, to translate to large-scale EV manufacturing, chromatography and ultrafiltration have been used for some time in order to concentrate and purify bioparticles [26] (e.”
BackgroundMethodGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Sandoval-Villegas, N., Nurieva, W., Amberger, M., & Ivics, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105084 · Cited by 159
Metadata
- Authors
- Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C.
- Affiliations
- Instituto de Biologia Experimental e Tecnológica (PT)
- Corresponding author
- Peixoto, Cristina
- ORCID
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-11-27
- Volume
- 20
- Issue
- 5
- Pages
- 451-465
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2990128831
- Cited by
- 123
- References
- 163
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 23 · 2023: 18 · 2022: 21 · 2021: 20 · 2020: 9
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Opinion on Biological Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- production problems, virus-like particles, extracellular vesicles, gene therapy, oncolytic virotherapy, cancer vaccines, downstream purification, continuous production, single-use technology, analytical methods
- MeSH terms
- Extracellular Vesicles, Antibodies, Monoclonal, Biological Products, Drug Industry, Viruses, Vaccines, Virus-Like Particle
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current challenges in biotherapeutic particles manufacturing. https://app.cochat.ai/papers/10.1080/14712598.2020.1693541
- The paper
- Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020). Current challenges in biotherapeutic particles manufacturing. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1693541
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.